Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1907598 Target Snapshot

Integrin alpha-V/beta-3 · PROTEIN COMPLEX · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,042Compounds
332Assays
3Approved Drugs
2,372.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Integrin alpha-V/beta-3 shows approved-linked disease relevance led by intermediate coronary syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P05106. Start with intermediate coronary syndrome, then reuse UniProt P05106 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with intermediate coronary syndrome, then reuse UniProt P05106 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
intermediate coronary syndrome

Integrin alpha-V/beta-3 shows approved-linked disease relevance led by intermediate coronary syndrome. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with intermediate coronary syndrome because it currently carries approved-linked support. Linked drugs include ABCIXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Integrin alpha-V/beta-3 as ChEMBL target CHEMBL1907598, mapped to UniProt P05106. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Integrin alpha-V/beta-3
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1907598
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P05106
Integrin beta-3
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Integrin alpha-V/beta-3 is the right protein anchor across sources, using UniProt P05106 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why intermediate coronary syndrome is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameIntegrin alpha-V/beta-3
Target TypePROTEIN COMPLEX
OrganismHomo sapiens
UniProtP05106
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelIntegrin beta-3
UniProt AccessionP05106
Component TypeProtein
Sequence Length788 aa

Integrin beta-3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Integrin alpha-V/beta-3, mapped to UniProt P05106. ChEMBL maps the protein component as Integrin beta-3. Sequence length is 788 aa.

Mapped IDP05106
Review nameIntegrin alpha-V/beta-3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Integrin alpha-V/beta-3 shows approved-linked disease relevance led by intermediate coronary syndrome. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
intermediate coronary syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugABCIXIMAB
Approved-linked Approved
Recurrent thrombophlebitis
1 linked drug · 1 direct · 1 efficacy
Linked drugABCIXIMAB
Late clinical Phase III
acute disease
1 linked drug · 1 direct · 1 efficacy
Linked drugABCIXIMAB
Late clinical Phase III
acute myocardial infarction
1 linked drug · 1 direct · 1 efficacy
Linked drugABCIXIMAB
Late clinical Phase III
adult glioblastoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCILENGITIDE
Late clinical Phase III
brain ischemia
1 linked drug · 1 direct · 1 efficacy
Linked drugABCIXIMAB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with intermediate coronary syndrome because it currently carries approved-linked support. Linked drugs include ABCIXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseintermediate coronary syndrome
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase III
5
Phase I
Assay Mix

Activity Type Distribution

IC502,113.0
KI229.0
EC5025.0
KD5.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL378530 10.52 IC50 0.03 Preclinical
CHEMBL410050 10.52 IC50 0.03 Preclinical
CHEMBL1180969 10.48 IC50 0.033 Preclinical
CHEMBL116123 10.4 IC50 0.04 Preclinical
CHEMBL151142 10.4 IC50 0.04 Preclinical
CHEMBL357486 10.4 IC50 0.04 Preclinical
CHEMBL5268482 10.4 IC50 0.04 Preclinical
CHEMBL2071603 10.37 Ki 0.043 Preclinical
CHEMBL87372 10.26 IC50 0.055 Preclinical
CHEMBL314636 10.25 IC50 0.056 Preclinical
Distribution

pChEMBL Value Distribution

99
5.0
94
5.5
192
6.0
194
6.5
229
7.0
229
7.5
261
8.0
287
8.5
227
9.0
87
9.5
pChEMBL
Approved Drugs

Approved Drugs

TIROFIBAN
CHEMBL916
Approved 1998
Properties Compare Identifier
EPTIFIBATIDE
CHEMBL1174
Approved 1998
Properties Compare Identifier
PACLITAXEL
CHEMBL428647
Approved 1992
Properties Compare Identifier
Assay Landscape

Assay Landscape

332
Total Assays
1,602
Tested Compounds
3
Assay Types
Binding — 298 assays, 1,602 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 162 1,167 7.8
cell-based format 126 418 7.4
assay format 8 10 7.5
cell-free format 1 0 —
single protein format 1 7 7.6
Functional — 23 assays, 188 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 19 128 6.5
assay format 4 60 7.8
ADME — 11 assays, 35 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 8 2 5.2
protein complex format 3 33 6.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine